A needle is a single-use instrument

The aseptic sequence is short and it is routinely compressed. Wash hands. Swab the vial stopper with alcohol and allow it to dry, because a wet stopper carries organisms into the vial on the needle. Swab the skin and allow that to dry too, both for antisepsis and because injecting through wet alcohol stings and is what people mistakenly attribute to the drug. Use a new needle. None of this is demanding, and all of it is what stands between a multi-dose vial and a contaminated one.

What the diluent changes, and what it does not

The diluent has no effect on the arithmetic and a substantial effect on everything else. Bacteriostatic water contains a preservative, conventionally benzyl alcohol at around nine tenths of a per cent, which inhibits microbial growth and is what makes repeated puncture of a multi-dose vial defensible. Sterile water for injection contains no preservative and offers no protection after the first puncture. Sodium chloride solution is isotonic and generally more comfortable on injection, and preserved and unpreserved presentations both exist.

The choice is therefore a sterility decision rather than a convenience one. A vial that will be entered more than once and kept for weeks is a different proposition from a single-use preparation, and the presence or absence of a preservative is the difference.

Two cautions belong here. Benzyl alcohol is not appropriate in all populations and is specifically avoided in neonates. And no preservative rescues poor technique: bacteriostatic means growth-inhibiting, not sterilising, and a stopper swabbed carelessly with a needle passed through a wet surface will introduce organisms that the preservative was never intended to handle. The diluent is a margin, not a permission.

Priming, and what skipping it costs

Pen devices require a priming step — commonly a dial to two units and an expulsion until a drop appears at the needle tip — before each injection. It serves two functions: expelling air that has accumulated in the cartridge and needle, and confirming that the device and needle are patent before a dose is dialled.

Skipping it produces an intermittent underdose. Air occupies part of the delivered volume, so some of the dialled dose is gas. Because the loss is variable and invisible, the person experiences an occasional week that felt different rather than a device error, and the habit erodes precisely because the feedback is unreliable.

Two adjacent points belong with it. A pen needle should be attached immediately before use and removed immediately after, because a needle left in place allows solution to leak out and air to be drawn in, which is how cartridges come to contain air in the first place. And the ten-second hold at the end of an injection — plunger fully depressed, needle still in the skin — exists because delivery is not instantaneous at these bore sizes, and withdrawing early leaves part of the dose on the skin. Both are omitted routinely.

Storage, and the in-use period nobody can give you

Lyophilised peptide is generally stored refrigerated at two to eight degrees, and is considerably more stable dry than in solution — which is the entire reason it is supplied as a powder. After reconstitution, degradation proceeds by hydrolysis, oxidation, aggregation and adsorption to container surfaces, at rates depending on sequence, buffer, temperature, light exposure and headspace.¹

For licensed products the in-use period is established by formal stability testing and printed on the carton, commonly twenty-eight days for a pen in use. For a peptide reconstituted at home there is no such study, and the numbers circulating in this market are extrapolations from other molecules, other buffers and other containers.

Three practical points survive that uncertainty. Cold slows every degradation route, so refrigeration is unambiguously better than ambient storage. Agitation promotes aggregation, so a vial should be swirled or the diluent run down the wall rather than shaken. And repeated temperature cycling — out for a dose, back in the door of the fridge, out again — is worse than steady cold, which argues against storing a vial in the door.

Anybody quoting a precise expiry for a home-reconstituted peptide is quoting a guess. The Journal would rather say so than repeat a number that sounds authoritative.

Sharps disposal

A used needle is a biohazard to whoever encounters it next, most often a waste worker. In most jurisdictions disposal of sharps in household waste is prohibited, and in all of them it is a route by which a stranger is injured.

The mechanism is simple and free almost everywhere: a rigid, puncture-resistant sharps container, filled to the marked line and no further, returned to a community pharmacy, a local authority collection point, a needle-exchange service or a clinical waste scheme. Improvised containers — a detergent bottle, a coffee tin — are widely used and generally accepted by collection services when rigid and sealed, though a purpose-made container is inexpensive.

Needle-clipping devices exist and remove the sharp tip. They reduce but do not eliminate the hazard and do not remove the disposal obligation.

The Journal raises this for a specific reason. We have heard from readers with two or three years of accumulated sharps in a drawer, kept there because they did not know where to take them and did not want to explain what they were for. Collection services are not interested in the contents of your vials. That is a real barrier built entirely out of anticipated judgement, and it is worth naming so that it can be dismissed.

Four things about this that are genuinely unestablished

First, the in-use stability of home-reconstituted peptides. No sequence-specific, buffer-specific, container-specific stability study exists for the great majority of what is sold in this market, and the figures in circulation are extrapolations.

Second, whether the injection-site interchangeability established for licensed acylated agonists holds for material of uncertain formulation. The mechanism suggests it should; nobody has measured it.

Third, the real-world frequency of the errors catalogued above. Our ranking comes from correspondence, which is a self-selected sample that over-represents people who noticed. The denominator is unknown.

Fourth, whether any of the technique measures described here changes outcomes in this specific population. They are supported by anatomical evidence and by the insulin literature; a trial in incretin users has not been done and probably will not be.²

Readers who know of stability data or technique trials we have missed should write to standards@compoundjournal.com. This is one of the files where we would most like to be corrected, because the current state is that millions of injections a week are being given on the basis of transferred evidence and a four-line calculation.

One thing we would like to see changed is trivially achievable. Needles are cheap, and reuse is driven almost entirely by cost and availability rather than by any belief that it is safe. Of every technique failure catalogued above, that is the one most responsive to supply, and the one where the barrier is commercial rather than educational.